vs

Side-by-side financial comparison of Cadre Holdings, Inc. (CDRE) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.

Varex Imaging Corp is the larger business by last-quarter revenue ($209.6M vs $167.2M, roughly 1.3× Cadre Holdings, Inc.). Cadre Holdings, Inc. runs the higher net margin — 7.0% vs 1.1%, a 5.9% gap on every dollar of revenue. On growth, Varex Imaging Corp posted the faster year-over-year revenue change (4.9% vs -5.0%). Cadre Holdings, Inc. produced more free cash flow last quarter ($18.0M vs $-26.8M). Over the past eight quarters, Cadre Holdings, Inc.'s revenue compounded faster (10.1% CAGR vs 0.8%).

RealCadre LLC, commonly Cadre, is an American financial technology company that provides individuals and institutions direct access to real estate investment properties, including commercial properties based in New York. The business and financial press describe it as a platform that "makes the real estate market more like the stock market" by allowing investors to select the individual transactions in which they participate, while investing a smaller amount than would be required to fully fu...

Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.

CDRE vs VREX — Head-to-Head

Bigger by revenue
VREX
VREX
1.3× larger
VREX
$209.6M
$167.2M
CDRE
Growing faster (revenue YoY)
VREX
VREX
+9.9% gap
VREX
4.9%
-5.0%
CDRE
Higher net margin
CDRE
CDRE
5.9% more per $
CDRE
7.0%
1.1%
VREX
More free cash flow
CDRE
CDRE
$44.8M more FCF
CDRE
$18.0M
$-26.8M
VREX
Faster 2-yr revenue CAGR
CDRE
CDRE
Annualised
CDRE
10.1%
0.8%
VREX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CDRE
CDRE
VREX
VREX
Revenue
$167.2M
$209.6M
Net Profit
$11.7M
$2.3M
Gross Margin
43.4%
33.3%
Operating Margin
12.2%
7.3%
Net Margin
7.0%
1.1%
Revenue YoY
-5.0%
4.9%
Net Profit YoY
-9.6%
866.7%
EPS (diluted)
$0.22
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDRE
CDRE
VREX
VREX
Q1 26
$209.6M
Q4 25
$167.2M
$228.9M
Q3 25
$155.9M
$203.0M
Q2 25
$157.1M
$212.9M
Q1 25
$130.1M
$199.8M
Q4 24
$176.0M
Q3 24
$109.4M
$205.7M
Q2 24
$144.3M
$209.1M
Net Profit
CDRE
CDRE
VREX
VREX
Q1 26
$2.3M
Q4 25
$11.7M
$12.2M
Q3 25
$10.9M
$-89.1M
Q2 25
$12.2M
$6.9M
Q1 25
$9.2M
$-300.0K
Q4 24
$13.0M
Q3 24
$3.7M
$-51.1M
Q2 24
$12.6M
$1.4M
Gross Margin
CDRE
CDRE
VREX
VREX
Q1 26
33.3%
Q4 25
43.4%
34.0%
Q3 25
42.7%
33.3%
Q2 25
40.9%
36.0%
Q1 25
43.1%
34.3%
Q4 24
43.9%
Q3 24
36.6%
32.6%
Q2 24
40.6%
32.0%
Operating Margin
CDRE
CDRE
VREX
VREX
Q1 26
7.3%
Q4 25
12.2%
8.6%
Q3 25
12.0%
-39.8%
Q2 25
9.3%
10.4%
Q1 25
10.4%
5.6%
Q4 24
16.7%
Q3 24
5.0%
5.3%
Q2 24
13.8%
4.4%
Net Margin
CDRE
CDRE
VREX
VREX
Q1 26
1.1%
Q4 25
7.0%
5.3%
Q3 25
7.0%
-43.9%
Q2 25
7.8%
3.2%
Q1 25
7.1%
-0.2%
Q4 24
7.4%
Q3 24
3.3%
-24.8%
Q2 24
8.7%
0.7%
EPS (diluted)
CDRE
CDRE
VREX
VREX
Q1 26
$0.05
Q4 25
$0.22
$0.29
Q3 25
$0.27
$-2.15
Q2 25
$0.30
$0.17
Q1 25
$0.23
$-0.01
Q4 24
$0.32
Q3 24
$0.09
$-1.25
Q2 24
$0.31
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDRE
CDRE
VREX
VREX
Cash + ST InvestmentsLiquidity on hand
$122.9M
$125.6M
Total DebtLower is stronger
$367.6M
Stockholders' EquityBook value
$317.8M
$476.9M
Total Assets
$770.0M
$1.1B
Debt / EquityLower = less leverage
0.77×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDRE
CDRE
VREX
VREX
Q1 26
$125.6M
Q4 25
$122.9M
$155.1M
Q3 25
$150.9M
$152.6M
Q2 25
$137.5M
$223.0M
Q1 25
$133.4M
$212.6M
Q4 24
$124.9M
Q3 24
$93.0M
$200.5M
Q2 24
$105.9M
$190.0M
Total Debt
CDRE
CDRE
VREX
VREX
Q1 26
$367.6M
Q4 25
$367.5M
Q3 25
$367.5M
Q2 25
$567.2M
Q1 25
$567.0M
Q4 24
Q3 24
$443.4M
Q2 24
$443.1M
Stockholders' Equity
CDRE
CDRE
VREX
VREX
Q1 26
$476.9M
Q4 25
$317.8M
$472.6M
Q3 25
$340.4M
$455.3M
Q2 25
$332.5M
$549.7M
Q1 25
$317.6M
$540.2M
Q4 24
$311.5M
Q3 24
$300.3M
$529.1M
Q2 24
$299.4M
$581.2M
Total Assets
CDRE
CDRE
VREX
VREX
Q1 26
$1.1B
Q4 25
$770.0M
$1.1B
Q3 25
$792.1M
$1.1B
Q2 25
$794.4M
$1.4B
Q1 25
$656.3M
$1.3B
Q4 24
$652.7M
Q3 24
$616.6M
$1.2B
Q2 24
$620.6M
$1.3B
Debt / Equity
CDRE
CDRE
VREX
VREX
Q1 26
0.77×
Q4 25
0.78×
Q3 25
0.81×
Q2 25
1.03×
Q1 25
1.05×
Q4 24
Q3 24
0.84×
Q2 24
0.76×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDRE
CDRE
VREX
VREX
Operating Cash FlowLast quarter
$21.3M
$-16.1M
Free Cash FlowOCF − Capex
$18.0M
$-26.8M
FCF MarginFCF / Revenue
10.7%
-12.8%
Capex IntensityCapex / Revenue
2.0%
5.1%
Cash ConversionOCF / Net Profit
1.81×
-7.00×
TTM Free Cash FlowTrailing 4 quarters
$56.8M
$-13.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDRE
CDRE
VREX
VREX
Q1 26
$-16.1M
Q4 25
$21.3M
$7.9M
Q3 25
$22.5M
$7.7M
Q2 25
$2.6M
$16.6M
Q1 25
$17.4M
$9.5M
Q4 24
$23.7M
Q3 24
$-5.2M
$25.9M
Q2 24
$11.1M
$8.0M
Free Cash Flow
CDRE
CDRE
VREX
VREX
Q1 26
$-26.8M
Q4 25
$18.0M
$2.3M
Q3 25
$21.6M
$1.4M
Q2 25
$1.2M
$9.8M
Q1 25
$16.1M
$5.3M
Q4 24
$22.4M
Q3 24
$-6.2M
$19.9M
Q2 24
$9.1M
$3.3M
FCF Margin
CDRE
CDRE
VREX
VREX
Q1 26
-12.8%
Q4 25
10.7%
1.0%
Q3 25
13.9%
0.7%
Q2 25
0.7%
4.6%
Q1 25
12.4%
2.7%
Q4 24
12.7%
Q3 24
-5.7%
9.7%
Q2 24
6.3%
1.6%
Capex Intensity
CDRE
CDRE
VREX
VREX
Q1 26
5.1%
Q4 25
2.0%
2.4%
Q3 25
0.5%
3.1%
Q2 25
0.9%
3.2%
Q1 25
1.0%
2.1%
Q4 24
0.7%
Q3 24
0.9%
2.9%
Q2 24
1.4%
2.2%
Cash Conversion
CDRE
CDRE
VREX
VREX
Q1 26
-7.00×
Q4 25
1.81×
0.65×
Q3 25
2.05×
Q2 25
0.21×
2.41×
Q1 25
1.88×
Q4 24
1.83×
Q3 24
-1.43×
Q2 24
0.89×
5.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDRE
CDRE

U.s.state And Local Agencies$72.7M43%
Other$48.6M29%
U.s.Federal Agencies$31.6M19%
Commercial$12.0M7%

VREX
VREX

Medical Segment$144.8M69%
Industrial Segment$64.8M31%

Related Comparisons